🌐 Entity
Treprostinil
Chemical compound
📊 Rating
3 news mentions · 👍 0 likes · 👎 0 dislikes
📌 Topics
- Healthcare (1)
- Biotechnology (1)
- Stock Rating Changes (1)
- Pharmaceutical Royalties (1)
- Market Volatility (1)
- Biopharmaceutical (1)
- Earnings Reports (1)
- Healthcare Stocks (1)
🏷️ Keywords
United Therapeutics (3) · Tyvaso DPI (2) · Leerink Conference (1) · pulmonary treatments (1) · pulmonary arterial hypertension (1) · clinical trials (1) · inhaled therapies (1) · MannKind (1) · RBC Capital (1) · Stock Downgrade (1) · Royalty Concerns (1) · Pharmaceutical Stocks (1) · Market Analysis (1) · UTHR stock (1) · Earnings beat (1) · Revenue miss (1) · Tyvaso (1) · Q4 results (1) · Healthcare stocks (1) · Inflation Reduction Act (1)
📖 Key Information
Treprostinil, sold under the brand names Remodulin for infusion, Orenitram for oral, and Tyvaso for inhalation among others, is a vasodilator that is used for the treatment of pulmonary arterial hypertension.
Treprostinil was approved for use in the United States in May 2002.
📰 Related News (3)
🔗 Entity Intersection Graph
People and organizations frequently mentioned alongside Treprostinil:
-
United Therapeutics · 2 shared articles -
RBC Capital Markets · 1 shared articles